Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2010-05-03
Target enrollment:
Participant gender:
Summary
Subjects will be entered into cohorts of 3 for the dose escalation phase so that the maximum
tolerated dose can be determined. 18 additional patients will be recruited once the maximum
tolerated dose (MTD) is determined for disease assessment.